- Home
- DXYZ vs PACB Comparison
DXYZ vs PACB Comparison
Compare DXYZ & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- PACB
- Stock Information
- Founded
- DXYZ N/A
- PACB 2000
- Country
- DXYZ
- PACB United States
- Employees
- DXYZ N/A
- PACB N/A
- Industry
- DXYZ
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- DXYZ
- PACB Industrials
- Exchange
- DXYZ Nasdaq
- PACB Nasdaq
- Market Cap
- DXYZ 413.3M
- PACB 364.2M
- IPO Year
- DXYZ 2024
- PACB 2010
- Fundamental
- Price
- DXYZ $32.87
- PACB $1.54
- Analyst Decision
- DXYZ
- PACB Buy
- Analyst Count
- DXYZ 0
- PACB 9
- Target Price
- DXYZ N/A
- PACB $2.06
- AVG Volume (30 Days)
- DXYZ N/A
- PACB 8.9M
- Earning Date
- DXYZ N/A
- PACB 08-07-2025
- Dividend Yield
- DXYZ N/A
- PACB N/A
- EPS Growth
- DXYZ N/A
- PACB N/A
- EPS
- DXYZ N/A
- PACB N/A
- Revenue
- DXYZ N/A
- PACB $152,357,000.00
- Revenue This Year
- DXYZ N/A
- PACB $3.33
- Revenue Next Year
- DXYZ N/A
- PACB $17.88
- P/E Ratio
- DXYZ N/A
- PACB N/A
- Revenue Growth
- DXYZ N/A
- PACB N/A
- 52 Week Low
- DXYZ N/A
- PACB $0.85
- 52 Week High
- DXYZ N/A
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- DXYZ N/A
- PACB 57.34
- Support Level
- DXYZ N/A
- PACB $1.35
- Resistance Level
- DXYZ N/A
- PACB $1.76
- Average True Range (ATR)
- DXYZ 0.00
- PACB 0.11
- MACD
- DXYZ 0.00
- PACB 0.00
- Stochastic Oscillator
- DXYZ 0.00
- PACB 46.34
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.